Biomarkers associated with checkpoint inhibitors (Q38819537)

6 September 2017

Biomarkers associated with checkpoint inhibitors (English)

1 reference

6 September 2017

0 references

3

A Marabelle

0 references

author name string

G Manson

1

1 reference

6 September 2017

J Norwood

2

1 reference

6 September 2017

A Marabelle

3

1 reference

6 September 2017

H Kohrt

4

1 reference

6 September 2017

R Houot

5

1 reference

6 September 2017

27 April 2016

1 reference

6 September 2017

1 reference

6 September 2017

27

1 reference

6 September 2017

7

1 reference

6 September 2017

1199-1206

1 reference

The blockade of immune checkpoints in cancer immunotherapy

6 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Immunologic correlates in the course of treatment with immunomodulating antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

CD73: A potential biomarker for anti-PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Signatures of mutational processes in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Molecular and genetic properties of tumors associated with local immune cytolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Differential regulation of indoleamine 2,3-dioxygenase by lipopolysaccharide and interferon gamma in murine bone marrow derived dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Ipilimumab: controversies in its development, utility and autoimmune adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

An immune-active tumor microenvironment favors clinical response to ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW181

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDW181

1 reference

release_w2h6q5rt7beupl5n6dlrg2jnuu

6 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/w2h6q5rt7beupl5n6dlrg2jnuu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference